Literature DB >> 12864717

Troponin testing: an audit in three metropolitan hospitals.

Richard X Davey1.   

Abstract

OBJECTIVE: To audit the appropriateness of use of a troponin I assay in three hospitals.
DESIGN: Cross-sectional survey of use of a troponin assay.
SETTING: Three hospitals in Melbourne, Victoria, each with an emergency department and a coronary care unit. PARTICIPANTS: Patients for whom a troponin I assay was requested between 1 and 7 May 2002, 27-42 months after introduction of the assay.
INTERVENTIONS: User-focused dissemination of relevant information, including protocols for use, from opinion leaders when the assay was introduced; continuous reinforcement of information in pathology reports. MAIN OUTCOME MEASURES: Adherence to protocol for assay use.
RESULTS: Troponin assays were requested for 333 patients during 351 symptom episodes. A single assay was used in 194 symptom episodes (55%), and serial assays in 157 (45%); proportions were statistically indistinguishable across all three hospitals (chi(2); P = 0.71). Of the 194 single assays, 13 (7%) diagnosed a myocardial infarction. Serial troponin testing in all three hospitals followed the suggested protocol, with mean time between serial assays being more than 6 hours at all hospitals.
CONCLUSIONS: Adherence to the protocol for serial troponin assay intervals was adequate, but single troponin assays were used extensively and probably inappropriately.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12864717     DOI: 10.5694/j.1326-5377.2003.tb05440.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Appropriateness of troponin testing in emergency department at a tertiary care hospital in Saudi Arabia.

Authors:  Maha Fahad S Alrusaiyes; Muhammad A Qureshi
Journal:  Saudi Med J       Date:  2022-05       Impact factor: 1.422

2.  Appropriate pathology ordering? Troponin testing within an Australian Emergency Department.

Authors:  F W Gardiner; S Zhai
Journal:  Ir J Med Sci       Date:  2016-06-24       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.